- Only 24% of women at high risk for breast cancer (BCa) opt for chemoprevention, according to a retrospective cohort study.
- Younger age (
Why this matters
- Chemoprevention with selective estrogen receptor modulations or aromatase inhibitors is a proven option for high-risk women to reduce BCa risk, as recommended by multiple organizations, including the US Preventive Services Task Force.
- Understanding risk factors for nonuse is key to targeting education and counseling.
- Retrospective cohort of 1506 women enrolled in a high-risk screening program from 2014 to 2017 at the Memorial Sloan Kettering Cancer Center in New York City.
- Funding: NIH
- 24% of the cohort had prior/current chemoprevention.
- Having multiple risk factors for chemoprevention (e.g., having family history or lobular carcinoma in situ), occurring in 38.6% of the cohort, did not increase the likelihood of use.
- In women with a documented discussion regarding chemoprevention (n=575), fear of adverse effects was the single most common reason for refusal (n=57/156 patients who refused).
- 61% of women who started chemoprevention completed it (5 years).
- Single-center study.
- Retrospective, observational design.